-- RBC Capital Markets 的分析師在周一透過電子郵件發送的報告中指出，RPM International (RPM) 的長期合約和價格遞增機制有助於其抵禦近期中東相關不確定性的影響。 分析師表示，衝突的穩定可能有助於 RPM 實現其第四財季息稅前利潤 (EBIT) 成長預期的高端，即低個位數至高個位數，但衝突的持續則可能導致預期下限的下降。 RBC 表示，RPM 強勁的基本面、第三財季 1 億美元的年度銷售、管理及行政費用 (SG&A) 節省，以及其強調中東業務佔比不到 4% 等因素都「令人印象深刻」。 分析師將該公司第四財季和 2026 財年的每股收益預期分別從 1.73 美元和 5.15 美元上調至 1.81 美元和 5.45 美元。 RBC 對該股票維持「跑贏大盤」評級，並將目標價從 126 美元上調至 130 美元。
Price: $107.34, Change: $-1.86, Percent Change: -1.70%
Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.
Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%
BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%